Early pregnancy exposure to selective @entity750 reuptake inhibitors, risks of XXXX , and hypothesized teratogenic mechanisms.

@entity154 @entity308 @entity146 @entity600 @entity750 @entity299 @entity1154
INTRODUCTION: Selective @entity750 reuptake inhibitors (SSRIs) are commonly used to manage antenatal @entity308 . Hence, the aim of this systematic review is to assess the prevalence of @entity600 associated with pregnancy exposure to such agents and summarize the hypothesized teratogenic mechanisms. Areas covered: Medical literature published in English (1980 - June 2015) was electronically searched to identify all articles reporting an increased prevalence of @entity600 associated with prenatal SSRI exposure and hypothesizing teratogenic mechanisms. Expert opinion: The only recurrent pattern of @entity154 associated with antenatal SSRI exposure is @entity299 . SSRIs may alter the function of @entity750 and related receptors which are involved in the development of the @entity1154 -dependent @entity299 . Nevertheless, the magnitude of this increase and, thus, its clinical significance are unclear. Therefore, a cautious approach of using SSRI during pregnancy only in the case of major @entity308 episodes should be applied. However, this risk should be balanced against the risks associated with the worsening of @entity308 , and take into consideration the large number of studies that found no associations between transplacental SSRI exposure and @entity299 . Prenatal ultrasonography and Doppler sonography to detect early @entity299 are also advisable. Non-pharmacological approaches are preferred for less severe @entity146 .
